Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Selective inhibition of human immunodeficiency virus (HIV) by 3′-Azido-2′,3′-dideoxyguanosine invitro — Masanori Baba (1987) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Selective inhibition of human immunodeficiency virus (HIV) by 3′-Azido-2′,3′-dideoxyguanosine invitro
Shared by
De Clercq Erik
KU Leuven
Selective inhibition of human immunodeficiency virus (HIV) by 3′-Azido-2′,3′-dideoxyguanosine invitro
Article
1987
en
Authors
+2 more
MB
Masanori Baba
RP
Rudi Pauwels
JB
Jan Balzarini
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
1987
The 2′,3′-dideoxyriboside of 2,6-diaminopurine selectively inhibits human immunodeficiency virus (HIV) replication invitro
Jan Balzarini
,
Rudi Pauwels
,
Masanori Baba
,
Morris J. Robins
,
Ruiming Zou
,
Piet Herdewijn
,
De Clercq Erik
Article
1988
Fuchsin acid selectively inhibits human immunodeficiency virus (HIV) replication invitro
Masanori Baba
,
Dominique Schols
,
Rudi Pauwels
,
Jan Balzarini
,
De Clercq Erik
Article
1992
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
De Clercq Erik
,
Naoki Yamamoto
,
Rudi Pauwels
,
Masanori Baba
,
Dominique Schols
,
Hiroshi Nakashima
,
Jan Balzarini
,
Zeger Debyser
,
Barry A. Murrer
,
David H. Schwartz
Article
1992
Highly potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by the HIV-1-specific reverse transcriptase inhibitors
Masanori Baba
,
Zeger Debyser
,
Shirô Shigeta
,
De Clercq Erik
Article
1989
5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine.
Jan Balzarini
,
Arthur Van Aerschot
,
Rudi Pauwels
,
Masanori Baba
,
Dominique Schols
,
Piet Herdewijn
,
De Clercq Erik
Discussion(0)
No comments yet. Be the first to comment.